JP7682850B2 - カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体 - Google Patents

カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体 Download PDF

Info

Publication number
JP7682850B2
JP7682850B2 JP2022504580A JP2022504580A JP7682850B2 JP 7682850 B2 JP7682850 B2 JP 7682850B2 JP 2022504580 A JP2022504580 A JP 2022504580A JP 2022504580 A JP2022504580 A JP 2022504580A JP 7682850 B2 JP7682850 B2 JP 7682850B2
Authority
JP
Japan
Prior art keywords
compound
amino
pyridine
acetyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504580A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021014172A5 (https=
JP2022541638A5 (https=
JP2022541638A (ja
Inventor
スティーブン コリングウッド，
クレイグ バクストン，
マシュー ハブグッド，
ジョナサン デーヴィッド ハーグレイヴ，
トーマス ボーレガード ショーフィールド，
マシュー スミス，
クリストファー スティムソン，
Original Assignee
ティエムイーエム１６エー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティエムイーエム１６エー リミテッド filed Critical ティエムイーエム１６エー リミテッド
Publication of JP2022541638A publication Critical patent/JP2022541638A/ja
Publication of JPWO2021014172A5 publication Critical patent/JPWO2021014172A5/ja
Publication of JP2022541638A5 publication Critical patent/JP2022541638A5/ja
Application granted granted Critical
Publication of JP7682850B2 publication Critical patent/JP7682850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022504580A 2019-07-24 2020-07-24 カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体 Active JP7682850B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1910608.7 2019-07-24
GBGB1910608.7A GB201910608D0 (en) 2019-07-24 2019-07-24 Compounds
PCT/GB2020/051785 WO2021014172A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as calcium-activated chloride channel modulators

Publications (4)

Publication Number Publication Date
JP2022541638A JP2022541638A (ja) 2022-09-26
JPWO2021014172A5 JPWO2021014172A5 (https=) 2023-07-25
JP2022541638A5 JP2022541638A5 (https=) 2023-07-25
JP7682850B2 true JP7682850B2 (ja) 2025-05-26

Family

ID=67839705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504580A Active JP7682850B2 (ja) 2019-07-24 2020-07-24 カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体

Country Status (6)

Country Link
US (1) US12545658B2 (https=)
EP (1) EP4003977B1 (https=)
JP (1) JP7682850B2 (https=)
CN (1) CN114929683B (https=)
GB (1) GB201910608D0 (https=)
WO (1) WO2021014172A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508422A (ja) 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプタ結合複素環式化合物
US20140309427A1 (en) 2013-02-06 2014-10-16 Wayne State University Substituted Pyran Derivatives
WO2018138362A1 (en) 2017-01-27 2018-08-02 Genfit N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases
WO2018195127A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Substituted 2-acylamino-cycloakylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
JP2019513778A (ja) 2016-04-15 2019-05-30 エピザイム，インコーポレイティド Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) * 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
US6262040B1 (en) * 1996-09-04 2001-07-17 Pfizer Inc Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
AU2016247768B2 (en) * 2015-04-17 2019-03-07 Corteva Agriscience Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508422A (ja) 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプタ結合複素環式化合物
US20140309427A1 (en) 2013-02-06 2014-10-16 Wayne State University Substituted Pyran Derivatives
JP2019513778A (ja) 2016-04-15 2019-05-30 エピザイム，インコーポレイティド Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
WO2018138362A1 (en) 2017-01-27 2018-08-02 Genfit N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases
WO2018195127A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Substituted 2-acylamino-cycloakylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAMKUNG, W. et al.，Small-molecule activators of TMEM16A, a calciumactivated chloride channel, stimulate epithelial chloride secretion and intestinal contraction，The FASEB Journal，2011年，Vol.25, No.11，pp.4048-4062，DOI:10.1096/fj.11-191627
NAMKUNG, W. et al.，TMEM16A Inhibitors Reveal TMEM16A as a Minor Component of Calcium-activated Chloride Channel Conductance in Airway and Intestinal Epithelial Cells，THE JOURNAL OF BIOLOGICAL CHEMISTRY，2011年，Vol.286, No.3，pp.2365-2374，DOI:10.1074/jbc.M110.175109

Also Published As

Publication number Publication date
CN114929683A (zh) 2022-08-19
US20220144803A1 (en) 2022-05-12
EP4003977B1 (en) 2026-04-15
EP4003977A1 (en) 2022-06-01
WO2021014172A1 (en) 2021-01-28
GB201910608D0 (en) 2019-09-04
US12545658B2 (en) 2026-02-10
CN114929683B (zh) 2024-09-03
JP2022541638A (ja) 2022-09-26

Similar Documents

Publication Publication Date Title
US12377105B2 (en) Compounds
US20200361871A1 (en) Compounds
US12415793B2 (en) Modulators of TMEM16A for treating respiratory disease
US20220235006A1 (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
US12552770B2 (en) Compounds for treating respiratory disease
JP7682850B2 (ja) カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体
JP7853981B2 (ja) 呼吸器疾患を治療するためのベンゾイミダゾール誘導体
HK40075169A (en) Pyridine derivatives as calcium-activated chloride channel modulators
US20240132467A1 (en) Benzimidazole derivatives for treating respiratory disease
HK40075169B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
HK40067765A (en) Modulators of tmem16a for treating respiratory disease
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7682850

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150